HONG KONG – China and U.S.-based Zai Lab Ltd. has signed on to develop and commercialize REGN-1979, a CD20xCD3 bispecific antibody from Regeneron Pharmaceuticals Inc., of Tarrytown, N.Y.
HONG KONG – China and U.S.-based Zai Lab Ltd. has signed on to develop and commercialize REGN-1979, a CD20xCD3 bispecific antibody from Regeneron Pharmaceuticals Inc., of Tarrytown, N.Y.
DUBLIN – Les Laboratoires Servier SAS has thrown its partner Symphogen A/S a lifeline by agreeing to a takeover deal in which the Danish firm will become Servier’s center of excellence for antibody development.
DUBLIN – Ethris GmbH and Neurimmune AG have formed a collaboration to develop nebulized, mRNA-encoded monoclonal antibodies directed at SARS-CoV-2, which will be delivered directly to the lungs of patients with COVID-19.
BEIJING – Suzhou-based Innovent Biologics Inc. has inked a deal with Alector Inc. to obtain the rights of the U.S. biotech’s AL-008 to develop and commercialize it for oncology indications in China.
BEIJING – Suzhou-based Innovent Biologics Inc. has inked a deal with Alector Inc. to obtain the rights of the U.S. biotech’s AL-008, a dual function anti-SIRP-alpha (anti-signal regulatory protein-alpha) antibody, to develop and commercialize it for oncology indications in China.
HONG KONG – Korean biopharma Celltrion Inc. said it’s halfway through the process of creating a super antibody to reign in the COVID-19 novel coronavirus that has claimed almost 13,000 lives globally.
HONG KONG – Korean biopharma Celltrion Inc. said it’s halfway through the process of creating a super antibody to reign in the COVID-19 novel coronavirus that has claimed almost 13,000 lives globally.
BEIJING – Zhongshan-based Akeso Inc., which focuses on bispecific antibodies, is again seeking pre-revenue listing on the Hong Kong Stock Exchange (HKEX), after its first IPO attempt failed to go through in December. The move comes at a time when analysts believe the coronavirus outbreak is weighing on the city’s IPO market. The second application, submitted on Feb. 3, was again supported by Morgan Stanley and J.P. Morgan. The clinical-stage biotech is reportedly seeking $300 million to support its R&D through the IPO, particularly its core asset, AK-104, a PD-1/CTLA4 bispecific antibody.
BEIJING – Zhongshan-based Akeso Inc., which focuses on bispecific antibodies, is again seeking pre-revenue listing on the Hong Kong Stock Exchange (HKEX), after its first IPO attempt failed to go through in December. The move comes at a time when analysts believe the coronavirus outbreak is weighing on the city’s IPO market.
RSS
